Login to Your Account

Other News To Note

Wednesday, February 27, 2013
• CytoDyn Inc., of Portland, Ore., said it entered a research collaboration with the Scripps Research Institute to study the firm's humanized anti-CCR5 antibody, PRO 140, in a pre-exposure prophylaxis model of HIV infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription